{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Complete Remission Without Platelet Recovery (CRi)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Complete Response (CRp)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"No Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"Response according to International Working Group response criteria for Acute myeloid leukemia (AML) (JCO 2003; 21: 4642-9): CR defined by presence of \\<5% blasts in the bone marrow (BM), with \\>1 X 10\\^9/L neutrophils and \\>100 x 10\\^9/L platelets in the peripheral blood (PB) with no detectable extramedullary disease. Participants who met the above criteria but had neutrophil or platelet counts less than the stated values were considered to have achieved CRi (CR with incomplete recovery of PB counts) or CR with incomplete platelet recovery (CRp) if CR but platelets \\< 100 x 10\\^9/L but ≥ 50 x 10\\^9/L and platelet transfusion independent. Partial response (PR) required all of the hematologic values for a CR but with a decrease of \\>/= 50% in the percentage of blasts to 5% to 25% in the BM aspirate.","groups":[{"description":"Azacitidine (AZA) 75 mg/m\\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib starting dose 200 mg orally twice a day for 28 Day cycle.","id":"OG000","title":"Azacitidine + Sorafenib"}],"paramType":"NUMBER","populationDescription":"Nine participants were not evaluable for response.","reportingStatus":"POSTED","timeFrame":"90 days","title":"Phase II: Number of Participants With Response","type":"SECONDARY","unitOfMeasure":"participants"}